Time for tocilizumab in COVID-19?
Intensive Care Med
.
2021 Jun;47(6):692-694.
doi: 10.1007/s00134-021-06441-y.
Epub 2021 May 31.
Authors
Ethan Butler
1
2
,
Marie Warrer Munch
3
,
Balasubramanian Venkatesh
4
5
Affiliations
1
Department of Intensive Care, Royal North Shore Hospital, St. Leonards, Australia.
[email protected]
.
2
Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
[email protected]
.
3
Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
4
Professor of Intensive Care, The Wesley Hospital, University of Queensland, Brisbane, Australia.
5
The George Institute for Global Health, University of New South Wales, Sydney, Australia.
PMID:
34057560
PMCID:
PMC8165681
DOI:
10.1007/s00134-021-06441-y
No abstract available
Publication types
Editorial
MeSH terms
Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Substances
Antibodies, Monoclonal, Humanized
tocilizumab